Comparative Pharmacology
Head-to-head clinical analysis: AZITHROMYCIN versus E BASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZITHROMYCIN versus E BASE.
AZITHROMYCIN vs E-BASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting mRNA translation and thus protein synthesis. Exhibits concentration-dependent bactericidal activity.
E-BASE is a proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing gastric acid secretion.
500 mg orally once daily for 3 days, or 500 mg IV once daily for at least 2 days followed by 500 mg orally to complete 7-10 days of therapy for community-acquired pneumonia. For other indications, typical adult dose is 500 mg orally on day 1 then 250 mg orally once daily on days 2-5.
25 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateAzithromycin + Norfloxacin
"Azithromycin may increase the QTc-prolonging activities of Norfloxacin."
Clinical Note
moderateAzithromycin + Ibandronate
"Azithromycin may increase the QTc-prolonging activities of Ibandronate."
Clinical Note
moderateAzithromycin + Indapamide
"Azithromycin may increase the QTc-prolonging activities of Indapamide."
Clinical Note
moderateAzithromycin + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Azithromycin resulting in a loss in efficacy."
Terminal half-life of approximately 68 hours (range 35–96 h) after multiple doses, allowing once-daily dosing and a prolonged post-antibiotic effect.
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal function; may be prolonged in renal impairment.
Primarily biliary/fecal (approx. 50% unchanged); renal excretion accounts for about 12% of the dose.
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Category A/B
Category C
Macrolide Antibiotic
Macrolide Antibiotic